- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
Latuda
Synonyms :
Class :
Atypical antipsychotics
Dosage Forms & Strengths
Tablet
20mg
40mg
60mg
80mg
120mg
Dosage Forms & Strengths
Tablet
20mg
40mg
60mg
80mg
120mg
Refer adult dosing
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
It may enhance the effects when combined with epinephrine by pharmacodynamic synergism
lurasidone: they may diminish the serum concentration of CYP3A4 Inducers
lurasidone: they may diminish the serum concentration of CYP3A4 Inducers
lurasidone: they may diminish the serum concentration of CYP3A4 Inducers
lurasidone: they may diminish the serum concentration of CYP3A4 Inducers
lurasidone: they may diminish the serum concentration of CYP3A4 Inducers
lurasidone: they may enhance the serum concentration of CYP3A4 Inhibitors
lurasidone: they may enhance the serum concentration of CYP3A4 Inhibitors
lurasidone: they may enhance the serum concentration of CYP3A4 Inhibitors
lurasidone: they may enhance the serum concentration of CYP3A4 Inhibitors
lurasidone: they may enhance the serum concentration of CYP3A4 Inhibitors
when both drugs are combined, there may be an increased effect of lurasidone by affecting hepatic or intestinal enzyme cyp3a4 metabolism
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may decrease the therapeutic effect when combined with antipsychotic agents
may have an increased arrhythmogenic effect when combined with mequitazine
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
the effect of lurasidone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of lurasidone
it decreases the effects of antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with sulpiride
antihypertensive agents increase the efficacy of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
antihypertensive agents increase the efficacy of antipsychotic agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines